Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Filter results: >>>>
Cell line Drug name Experimental replicate Timepoint Curve type (GR values) Curve type (relative cell counts) Experiment name Number of concentrations Cell doublings (DMSO control) GR50 GRmax GR_AOC GEC50 GRinf Hill slope (GR values) R-squared sigmoid fit (GR values) P-value sigmoid fit (GR values) R-squared flat fit (GR values) IC50 Emax AUC EC50 Einf Hill slope (relative cell counts) R-squared sigmoid fit (relative cell counts) P-value sigmoid fit (relative cell counts) R-squared flat fit (relative cell counts)
HCC1806 AZD-6482 3 72
flat
flat
HCC1806 AZD6482 0 3 72
8 3.201
Inf
1.0
0.00122
0.0
1.0
0.01
-0.0063
1.0
0.999
Inf
1.01
0.998
0.0
1.01
0.01
-0.00515
1.0
0.998
HCC1806 AZD-6482 1 72
flat
flat
HCC1806 AZD6482 0 1 72
8 2.748
Inf
1.0
0.00141
0.0
1.0
0.01
-0.00621
1.0
0.999
Inf
1.01
0.998
0.0
1.01
0.01
-0.00515
1.0
0.998
HCC1806 AZD-6482 2 72
flat
flat
HCC1806 AZD6482 0 2 72
8 2.833
Inf
1.0
0.00136
0.0
1.0
0.01
-0.0062
1.0
0.999
Inf
1.01
0.998
0.0
1.01
0.01
-0.00512
1.0
0.998
BT-549 XL147 2 72
flat
flat
BT549 pilaralisib 0 2 72
8 1.952
Inf
0.967
-0.00824
0.0
0.967
0.01
-0.000427
1.0
1.0
Inf
0.968
1.01
0.0
0.968
0.01
-0.000878
1.0
1.0
HCC1806 XL147 2 72
flat
flat
HCC1806 pilaralisib 0 2 72
8 2.817
Inf
1.02
0.000975
0.0
1.02
0.01
-4.46e-06
1.0
1.0
Inf
1.03
0.999
0.0
1.03
0.01
-0.000109
1.0
1.0
HCC1806 XL147 1 72
flat
flat
HCC1806 pilaralisib 0 1 72
8 2.732
Inf
1.02
0.00101
0.0
1.02
0.01
-4.53e-06
1.0
1.0
Inf
1.03
0.999
0.0
1.03
0.01
-0.000107
1.0
1.0
HCC1806 XL147 3 72
flat
flat
HCC1806 pilaralisib 0 3 72
8 3.185
Inf
1.02
0.000871
0.0
1.02
0.01
-2.12e-06
1.0
1.0
Inf
1.03
0.999
0.0
1.03
0.01
-0.000107
1.0
1.0